12 Metabolic effects of NAD and how they can impact your patient population. NAD research continues to mount up and shows that by increasing NAD in aging individuals there are significant health benefits. Recent research has shown that NAD can be a therapeutic target for metabolic disorders such as obesity, diabetes, dyslipidemia and fatty liver. NAD has been shown to be safe, well tolerated and can increase NAD levels in healthy volunteers.
12 metabolic effects of NAD that you should be talking to your patients about every day:
- Improved glucose tolerance
- Improved insulin sensitivity
- Improved insulin secretion
- Inhibition of inflammation
- Improved liver citrate synthase activity
- Enhanced mitochondiral biogenesis
- Suppressed body weight gain
- Improved glucose homeostasis
- Protection against diabetic neuropathy
- Reduced lipid accumulation
- Reduced fibrosis in the liver
- Improved metabolic flexibility
If you look at your practice how many patients do you have on your book today that could benefit from NAD therapy? Diabetics, pre-diabetics, overweight, obese, hyperlipidemia, fatty liver, alcoholic, arthritis, lupus, multiple sclerosis, rheumatoid arthritis, auto immune disease and the list will go on and on. NAD is fast becoming a major breakthrough in wellness medicine and anti aging. Give your patients access to this emerging therapy by calling us today. We offer complete NAD protocols to deliver this effective therapy to your patients.
References
Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–536. doi: 10.1016/j.cmet.2011.08.014
Gariani K, Menzies KJ, Ryu D, Wegner CJ, Wang X, Ropelle ER, Moullan N, Zhang H, et al. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology. 2016;63(4):1190–1204. doi: 10.1002/hep.28245.
Trammell SA, Weidemann BJ, Chadda A, Yorek MS, Holmes A, Coppey LJ, Obrosov A, Kardon RH, Yorek MA, Brenner C. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep. 2016;6:26933. doi: 10.1038/srep26933.
Zhou CC, Yang X, Hua X, Liu J, Fan MB, Li GQ, Song J, Xu TY, et al. Hepatic NAD (+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016;173(15):2352–2368. doi: 10.1111/bph.13513.
Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, et al. The NAD (+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–847. doi: 10.1016/j.cmet.2012.04.022.
Mitchell SJ, Bernier M, Aon MA, Cortassa S, Kim EY, Fang EF, Palacios HH, Ali A, et al. Nicotinamide improves aspects of Healthspan, but not lifespan, in mice. Cell Metab. 2018;27(3):667–76 e4. doi: 10.1016/j.cmet.2018.02.001.
Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia. 2011;54(12):3083–3092. doi: 10.1007/s00125-011-2288-0.
Uddin GM, Youngson NA, Sinclair DA, Morris MJ. Head to head comparison of short-term treatment with the NAD (+) precursor nicotinamide mononucleotide (NMN) and 6 weeks of exercise in obese female mice. Front Pharmacol. 2016;7:258. doi: 10.3389/fphar.2016.00258.
Shi Wenbiao, Hegeman Maria A., van Dartel Dorien A.M., Tang Jing, Suarez Manuel, Swarts Hans, van der Hee Bart, Arola Lluis, Keijer Jaap. Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet. Molecular Nutrition & Food Research. 2017;61(8):1600878. doi: 10.1002/mnfr.201600878.
